Chapter V. Beta-Cell Replacement

Rev Diabet Stud, 2012, 9(4):385-406

DOI 10.1900/RDS.2012.9.385

Islet Transplantation in Type 1 Diabetes: Ongoing Challenges, Refined Procedures, and Long-Term Outcome

A.M. James Shapiro

Clinical Islet Transplant Program, University of Alberta, 2000 College Plaza, 8215 112th Street, Edmonton AB Canada T6G 2C8

Manuscript submitted December 16, 2012; accepted January 21, 2013.

Keywords: diabetes, islet, transplantation, immunosuppression, allograft

Abstract

Remarkable progress has been made in islet transplantation over a span of 40 years. Once just an experimental curiosity in mice, this therapy has moved forward, and can now provide robust therapy for highly selected patients with type 1 diabetes (T1D), refractory to stabilization by other means. This progress could not have occurred without extensive dynamic international collaboration. Currently, 1,085 patients have undergone islet transplantation at 40 international sites since the Edmonton Protocol was reported in 2000 (752 allografts, 333 autografts), according to the Collaborative Islet Transplant Registry. The long-term results of islet transplantation in selected centers now match registry data of pancreas-alone transplantation, with 6 sites reporting five-year insulin independence rates ≥50%. Islet transplantation has been criticized for the use of multiple donor pancreas organs, but progress has also occurred in single-donor success, with 10 sites reporting increased single-donor engraftment. The next wave of innovative clinical trial interventions will address instant blood-mediated inflammatory reaction (IBMIR), apoptosis, and inflammation, and will translate into further marked improvements in single-donor success. Effective control of auto- and alloimmunity is the key to long-term islet function, and high-resolution cellular and antibody-based assays will add considerable precision to this process. Advances in immunosuppression, with new antibody-based targeting of costimulatory blockade and other T-B cellular signaling, will have further profound impact on the safety record of immunotherapy. Clinical trials will move forward shortly to test out new human stem cell derived islets, and in parallel trials will move forward, testing pig islets for compatibility in patients. Induction of immunological tolerance to self-islet antigens and to allografts is a difficult challenge, but potentially within our grasp.

Fulltext: HTML , PDF (327KB)

This article has been cited by other articles:

	Clinical pancreatic islet transplantation Shapiro AM, Pokrywczynska M, Ricordi C Nat Rev Endocrinol 2017. 13(5):268-277

	Sodium Hyaluronate Gel Containing bFGF Co-Transplanted with Islets Leading to the Promotion of Angiogenesis and the Reduction of the Required Grafted Islets in Diabetic Mice Qiu KY, Fu HX, Jiang X, Xu FY, Chen XS, Lin Q, He YQ, Zhou MT, Liu CY J Biomat Tiss Engin 2017. 7(4):291-301

	Microencapsulation in Clinical Islet Xenotransplantation Shimoda M, Matsumoto S Methods Mol Biol 2017. 1479:335-345

	Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations Tatum JA, Meneveau MO, Brayman KL Diabetes Metab Syndr Obes 2017. 10:73-78

	Clarifying intact 3D tissues on a microfluidic chip for high-throughput structural analysis Chen YY, Silva PN, Syed AM, Sindhwani S, Rocheleau JV, Chan WC Proc Natl Acad Sci USA 2016. 113(52):14915-14920

	GPER-novel membrane oestrogen receptor Zimmerman MA, Budish RA, Kashyap S, Lindsey SH Clin Sci (Lond) 2016. 130(12):1005-1016

	Does exercise pose a challenge to glucoregulation after clinical islet transplantation? Funk DR, Boule NG, Senior PA, Yardley JE Appl Physiol Nutr Metab 2016. In press

	Necessities for a Clinical Islet Program Hawthorne WJ Adv Exp Med Biol 2016. 938:67-88

	Size effect of engineered islets prepared using microfabricated wells on islet cell function and arrangement Ichihara Y, Utoh R, Yamada M, Shimizu T, Uchigata Y Heliyon 2016. 2(6):e00129

	Clinical intraocular islet transplantation is not a number issue Shishido A, Caicedo A, Rodriguez-Diaz R, Pileggi A, Berggren PO, Abdulreda MH Cell R4 2016. 4(4):e2120

	Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice Vegas AJ, Veiseh O, Gürtler M, Millman JR, Pagliuca FW, Bader AR, Doloff JC, Li J, Chen M, Olejnik K, Tam HH, Jhunjhunwala S, Langan E, Aresta-Dasilva S, Gandham S, McGarrigle JJ, Bochenek MA, Hollister-Lock J, Oberholzer J, Greiner DL, Weir GC, Melton DA, Langer R, Anderson DG Nat Med 2016. 22(3):306-311

	Chromatin Regulators in Pancreas Development and Diabetes Campbell SA, Hoffman BG Trends Endocrinol Metab 2016. 27(3):142-152

	Construction and Evaluation of Islet Transplantation Under the Kidney Capsule in Mice Fu HX, Wu LL, Qiu KY, Zhao YZ, Xu YY, Jiang X, Zhou MT, Zheng XT, Liu CY, Yang SL, Li XK J Biomat Tiss Engin 2016. 6(3):208-215

	A Comparative Analysis of the Safety, Efficacy, and Cost of Islet Versus Pancreas Transplantation in Nonuremic Patients With Type 1 Diabetes Moassesfar S, Masharani U, Frassetto LA, Szot GL, Tavakol M, Stock PG, Posselt AM Am J Transplant 2016. 16(2):518-526

	Current Concepts of Using Pigs as a Source for Beta-Cell Replacement Therapy of Type 1 Diabetes Klymiuk N, Ludwig B, Seissler J, Reichart B, Wolf E Curr Mol Biol Rep 2016. 2(2):73-82

	Gut microbiota imbalance and colorectal cancer Gagniere J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, Bringer MA, Pezet D, Bonnet M World J Gastroenterol 2016. 22(2):501-518

	Bone marrow derived stem cell therapy for type 2 diabetes mellitus Wehbe T, Chahine NA, Sissi S, Abou-Joaude I, Chalhoub L Stem Cell Investig 2016. 3:87

	Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade Blau JE, Abegg MR, Flegel WA, Zhao X, Harlan DM, Rother KI Am J Transplant 2015. 15(11):2995-3001

	Islet Amyloid in Whole Pancreas Transplants for Type 1 Diabetes Mellitus (DM): Possible Role of Type 2 DM for Graft Failure Leon Fradejas M, Kandil D, Papadimitriou JC, del Pino Florez Rial M, Prieto Sanchez E, Drachenberg CB Am J Transplant 2015. 15(9):2495-2500

	Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice Fousteri G, Jofra T, Di Fonte R, Battaglia M Plos One 2015. 10(6):e0127631

	Cellular therapies based on stem cells and their insulin-producing surrogates: a 2015 reality check Giannoukakis N, Trucco M Pediatr Diabetes 2015. 16(3):151-163

	Role of transcription factors in the transdifferentiation of pancreatic islet cells van der Meulen T, Huising MO J Mol Endocrinol 2015. 54(2):R103-R117

	Human pancreatic islet transplantation: an update and description of the establishment of a pancreatic islet isolation laboratory Rheinheimer J, Bauer AC, Silveiro SP, Estivalet AA, Boucas AP, Rosa AR, Souza BM, Oliveira FS, Cruz LA, Brondani LA, Azevedo MJ, Lemos NE, Carlessi R, Assmann TS, Gross JL, Leitao CB, Crispim D Arch Endocrinol Metab 2015. 59(2):161-170

	Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review Health Quality Ontario Ont Health Technol Assess Ser 2015. 15(16):1-84

	The potential use of cell-based therapies in the treatment of oral diseases Kagami H Oral Dis 2015. 21(5):545-549

	Bioengineered stem cells as an alternative for islet cell transplantation Moore SJ, Gala-Lopez BL, Pepper AR, Pawlick RL, Shapiro AM World J Transplant 2015. 5(1):1-10

	Cell sheet approach for tissue engineering and regenerative medicine Matsuura K, Utoh R, Nagase K, Okano T J Control Release 2014. 190:228-239

	Beta-cell differentiation of human pancreatic duct-derived cells after in vitro expansion Corritore E, Dugnani E, Pasquale V, Misawa R, Witkowski P, Piemonti L, Sokal EM, Lysy PA Cell Reprogram 2014. 16(6):456-466

	From Beta cell replacement to beta cell regeneration: implications for antidiabetic therapy Liu C, Wu H J Diabetes Sci Technol 2014. 8(6):1221-1226

	An Extremely Weak Electric Current System Induces Anti-apoptotic Effects and Anti-necrotic Effects in Living Cells Kojima D, Nishinakamura H, Itoh T, Kodama S Curr Tissue Engin 2014. 3(2):102-111

	Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3 van der Meulen T, Huising MO Rev Diabet Stud 2014. 11(1):115-132

	Islet and stem cell encapsulation for clinical transplantation Krishnan R, Alexander M, Robles L, Foster CE 3rd, Lakey JR Rev Diabet Stud 2014. 11(1):84-101

	In vitro differentiation and expansion of human pluripotent stem cell-derived pancreatic progenitors Chmielowiec J, Borowiak M Rev Diabet Stud 2014. 11(1):19-34

	Theranostic MRI: the future for Type 1 diabetes management? Wang P, Moore A Imaging Med 2014. 6(1):25-39

	Synergism of a natural plant product, oleanolic acid with calcineurin inhibitor in prolonging islet allograft survival Angaswamy N, Tiriveedhi V, Banan B, Benshoff N, Chapman W, Mohanakumar T Transpl Immunol 2013. 29(1-4):64-70

	Islet neogenesis: a possible pathway for Beta-cell replenishment Bonner-Weir S, Guo L, Li WC, Ouziel-Yahalom L, Weir GC, Sharma A Rev Diabet Stud 2012. 9(4):407-416

	Interleukin-1 antagonists and other cytokine blockade strategies for Type 1 diabetes Mandrup-Poulsen T Rev Diabet Stud 2012. 9(4):338-347